ScoreWhy is Arrowhead Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 2.95%, the company declared Outstanding results in Dec 25
- NET PROFIT(Q) At USD 30.81 MM has Grown at 7,656.35%
- OPERATING CASH FLOW(Y) Highest at USD 344.3 MM
- ROCE(HY) Highest at 65.14%
2
With ROE of 41.09%, it has a attractive valuation with a 14.13 Price to Book Value
- Over the past year, while the stock has generated a return of 263.03%, its profits have risen by 136% ; the PEG ratio of the company is 0.3
3
High Institutional Holdings at 96.34%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 263.03% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Arrowhead Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Arrowhead Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Arrowhead Pharmaceuticals, Inc.
292.06%
1.86
69.64%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
68.70%
EBIT Growth (5y)
36.13%
EBIT to Interest (avg)
-57.63
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.68
Sales to Capital Employed (avg)
0.36
Tax Ratio
1.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
96.34%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
14.13
EV to EBIT
25.63
EV to EBITDA
23.65
EV to Capital Employed
32.44
EV to Sales
7.06
PEG Ratio
0.26
Dividend Yield
NA
ROCE (Latest)
126.58%
ROE (Latest)
41.09%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
NET PROFIT(Q)
At USD 30.81 MM has Grown at 7,656.35%
OPERATING CASH FLOW(Y)
Highest at USD 344.3 MM
ROCE(HY)
Highest at 65.14%
PRE-TAX PROFIT(Q)
At USD 28.27 MM has Grown at 119.44%
RAW MATERIAL COST(Y)
Fallen by -187.48% (YoY
CASH AND EQV(HY)
Highest at USD 1,835.98 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -40.26 %
NET SALES(Q)
At USD 264.03 MM has Grown at 27.33%
-3What is not working for the Company
INTEREST(9M)
At USD 68.58 MM has Grown at 65.71%
Here's what is working for Arrowhead Pharmaceuticals, Inc.
Net Profit
At USD 30.81 MM has Grown at 7,656.35%
over average net sales of the previous four periods of USD -0.41 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Pre-Tax Profit
At USD 28.27 MM has Grown at 119.44%
over average net sales of the previous four periods of USD 12.88 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Operating Cash Flow
Highest at USD 344.3 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 264.03 MM has Grown at 27.33%
over average net sales of the previous four periods of USD 207.36 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Cash and Eqv
Highest at USD 1,835.98 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -40.26 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -187.48% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 6.39 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Arrowhead Pharmaceuticals, Inc.
Interest
At USD 68.58 MM has Grown at 65.71%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
